Crucell Posts 2Q Net Loss, Keeps FY09 Guidance
August 11 2009 - 2:34AM
Dow Jones News
Dutch biotechnology company Crucell NV (CRXL) Tuesday posted a
second-quarter net loss due to tax charges and currency effects,
but reported 32% revenue growth and confirmed its outlook for
2009.
The Dutch company, which makes vaccines for influenza,
children's diseases and hepatitis B, reported a second quarter net
loss of EUR1.8 million, compared with a net loss of EUR7.4 million
a year earlier. Revenue rose 32% to EUR78.7 million, mainly driven
by strong sales of Crucell's children's vaccine Quinvaxem.
Three analysts polled by Dow Jones Newswires forecast a net
profit of EUR4.6 million and revenue of EUR84.8 million.
Crucell reiterated its guidance for 2009, saying it expects
combined full-year 2009 total revenue and other operating income to
grow by 20% at constant currencies.
Crucell shares closed at EUR17.40 Monday and have gained nearly
60% year-to-date. In January, Crucell pulled out of friendly
takeover talks with U.S.-based Wyeth (WYE), which is set to merge
with Pfizer Inc. (PFE).
Company Web site: http://www.crucell.com
-By Maarten van Tartwijk; Dow Jones Newswires; +31 20 571 5201;
maarten.vantartwijk@dowjones.com